Phase 1 Study of the GPRC5DxCD3 Bispecific Talquetamab in Patients with RR Multiple Myeloma скачать в хорошем качестве

Phase 1 Study of the GPRC5DxCD3 Bispecific Talquetamab in Patients with RR Multiple Myeloma

A Phase 1, First-in-Human Study of Talquetamab, a G Protein-Coupled Receptor Family C Group 5 Member D (GPRC5D) x CD3 Bispecific Antibody, in Patients with Relapsed and/or Refractory Multiple Myeloma (RRMM) Talquetamab (JNJ-64407564) is a first-in-class bispecific antibody that binds to GPRC5D and CD3 to induce T cell-mediated killing of GPRC5D-expressing MM cells through the recruitment and activation of T cells. In preclinical models, talquetamab induced cell killing of primary MM cells and inhibited tumor formation and growth in MM mouse models. GPRC5D is a novel target for MM and in the first clinical report of this first-in-class agent, encouraging clinical activity with manageable safety was observed with talquetamab in heavily pretreated pts with RRMM. A MTD has not been defined and dose escalation continues, with the study nearing a RP2D. The encouraging clinical activity supports monotherapy development and combination approaches. Please subscribe to our channel! Subscribe to International Myeloma Foundation: http://bit.ly/XlUtPE Visit our website at: https://www.myeloma.org Find us online: Facebook:   / myeloma   Google+: http://gplus.to/imfmyeloma IMF on twitter: @IMFMyeloma (  / imfmyeloma  ) Dr. Durie on twitter: @BrianDurieMD (  / brianduriemd  ) Support the IMF! http://bit.ly/WskQHC Category Nonprofits & Activism License Standard YouTube License